Cardiac Changes in Myeloproliferative Neoplasms

Study Overview
=================
Brief Summary
-----------------
Myeloproliferative neoplasms are heterogeneous group of clonal hematopoietic stem cell neoplasms with excessive proliferation of one or more of the erythroid, megakaryocytic, or myeloid lineages and relatively normal maturation resulting in increased numbers of red cells, platelets, and/or granulocytes in the peripheral blood. Constitutive tyrosine kinase activation appears to be a common pathogenetic mechanism.

Detailed Description
-----------------
According to worldwide study of prevalence of myeloproliferative neoplasms revealed: Incidence of polycythemia vera ranged 0.01 to 2.61 per 100.000 population and the prevalence ranging from 0.49 to 46.88 per 100.000 population. Incidence of essential thrombocythemia is 0.21 to 2.27 per 100.000 population, prevalence ranging between 11.00 - 42.51 per 100.000 population. Primary myelofibrosis incidence is 1.15 -4.99 per 100.000 population and prevalence ranging between 1.76 - 4.05 per 100.000 population.In previous studies, cardiac involvement including coronary arterial thrombosis, myocardial infarction, pulmonary hypertension, asymptomatic pericardial effusion, cardiac tamponade, intractable cardiac failure due to intraventricular stenosis and valvular stenosis that occur in myeloproliferative neoplasms. There is a few number of studies in which cardiac lesions were evaluated in myeloproliferative neoplasms by using transthoracic echocardiography but still inadequate, so we need to understand more about cardiovascular complications in myeloproliferative neoplasms.

Official Title
-----------------
Functional and Morphological Cardiac Changes in Myeloproliferative Neoplasms

Conditions
-----------------
Myeloproliferative Neoplasm

Intervention / Treatment
-----------------
* Device: Transthorathic echocardiogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnostic criteria of myeloproliferative neoplasms. Exclusion Criteria: Extreme body weight e.g., morbid obesity. Cardiac disease. Cerebrovascular disorders. Diabetes mellitus. Dyslipidemia.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: study group<br>patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients. | Device: Transthorathic echocardiogram<br>* In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.<br>|
| Active Comparator: control group<br>patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities. | Device: Transthorathic echocardiogram<br>* In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.<br>|
| Active Comparator: control group 2<br>healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography. | Device: Transthorathic echocardiogram<br>* In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients with cardiac complications in myeloproliferative diseases. | cardiac complications as valvular changes, ejection fraction changes, pulmonary hypertension | 30 minutes |